Supplemental material
Current Medical Research and Opinion
Volume 34, 2018 - Issue 12
Reprints and Corporate Permissions
Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?
To request a reprint or corporate permissions for this article, please click on the relevant link below:
Academic Permissions
Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?
Obtain permissions instantly via Rightslink by clicking on the button below:
If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.
Related Research Data
Section 2. Psychological Treatments
Source:
SAGE Publications
Real-world effectiveness and safety of aripiprazole augmentation therapy in patients with major depressive disorder
Source:
Figshare
The Efficacy and Safety of Aripiprazole as Adjunctive Therapy in Major Depressive Disorder
Source:
Ovid Technologies (Wolters Kluwer Health)
Pharmacologic approaches to treatment resistant depression: Evidences and personal experience
Source:
Baishideng Publishing Group Inc.
Real-world effectiveness and safety of aripiprazole augmentation therapy in patients with major depressive disorder
Source:
Figshare
Real-world effectiveness and safety of aripiprazole augmentation therapy in patients with major depressive disorder
Source:
Figshare
Section 2. Psychological Treatments
Source:
SAGE Publications
Aripiprazole augmentation for treatment of patients with chronic or recurrent major depressive disorder
Source:
Ovid Technologies (Wolters Kluwer Health)
Real-world effectiveness and safety of aripiprazole augmentation therapy in patients with major depressive disorder
Source:
Figshare
Novel treatment options in depression and psychosis
Source:
Dove Medical Press Ltd.
The Efficacy and Safety of Aripiprazole as Adjunctive Therapy in Major Depressive Disorder
Source:
Physicians Postgraduate Press, Inc
Long-term safety and tolerability of open-label aripiprazole augmentation of antidepressant therapy in major depressive disorder
Source:
Dove Medical Press Ltd.
Section 2. Psychological Treatments
Source:
SAGE Publications
Effects of the dopamine agonist pramipexole on depression, anhedonia and motor functioning in Parkinson's disease
Source:
Elsevier BV
Backing into the future: pharmacological approaches to the management of resistant depression
Source:
Cambridge University Press (CUP)
Aripiprazole augmentation for major depressive disorder
Source:
Ovid Technologies (Wolters Kluwer Health)
Section 2. Psychological Treatments
Source:
SAGE Publications
Section 2. Psychological Treatments
Source:
SAGE Publications
Section 2. Psychological Treatments
Source:
SAGE Publications
Section 2. Psychological Treatments
Source:
SAGE Publications
Linking provided by
